Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer

Ogura, Takeshi; Yamao, Kenji; Hara, Kazuo; Mizuno, Nobumasa; Hijioka, Susumu; Imaoka, Hiroshi; Sawaki, Akira; Niwa, Yasumasa; Tajika, Masahiro; Kondo, Shinya; Tanaka, Tsutomu; Shimizu, Yasuhiro; Bhatia, Vikram; Higuchi, Kazuhide; Hosoda, Waki; Yatabe, Yasushi

doi:10.1007/s00535-012-0664-2

Cited by 94 publications

(84 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The activation of these pathways was involved in transformation, uncontrolled proliferation, invasion, and metastasis of pancreatic cancer cells (28). Detection of the Kras mutation status could be used to assess prognosis of pancreatic cancer (29)(30)(31). Moreover, the downstream targets of mutant Kras could also be used in the assessment of prognosis of pancreatic cancer (32).…”

Section: Discussionmentioning

confidence: 99%

Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Liang

Qin

Zhang

et al. 2017

Molecular Cancer Research

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Liang

Qin

Zhang

et al. 2017

Molecular Cancer Research

View full text Add to dashboard Cite

show abstract

“…One study found that KRAS G12D and G12R mutations are negative prognostic factors for overall survival (Ogura et al, 2013). However, a second study found that the presence of KRAS G12R alone correlates with increased overall survival, whereas the KRAS G12D mutation resulted in the shortest overall survival (Faris et al, 2014).…”

Section: Ras Mutation Hotspots -Structural Biological and Functionalmentioning

confidence: 99%

RAS isoforms and mutations in cancer at a glance

Hobbs

Der

Rossman

2016

Journal of Cell Science

666

709

View full text Add to dashboard Cite

RAS proteins (KRAS4A, KRAS4B, NRAS and HRAS) function as GDP-GTP-regulated binary on-off switches, which regulate cytoplasmic signaling networks that control diverse normal cellular processes. Gain-of-function missense mutations in RAS genes are found in ∼25% of human cancers, prompting interest in identifying anti-RAS therapeutic strategies for cancer treatment. However, despite more than three decades of intense effort, no anti-RAS therapies have reached clinical application. Contributing to this failure has been an underestimation of the complexities of RAS. First, there is now appreciation that the four human RAS proteins are not functionally identical. Second, with >130 different missense mutations found in cancer, there is an emerging view that there are mutation-specific consequences on RAS structure, biochemistry and biology, and mutation-selective therapeutic strategies are needed. In this Cell Science at a Glance article and accompanying poster, we provide a snapshot of the differences between RAS isoforms and mutations, as well as the current status of anti-RAS drug-discovery efforts.

show abstract

“…Among patients with K-ras mutations, those with the G12V mutation had a significantly longer overall survival than those with the G12D or G12R mutations 20 . In our two cases, although we measured the K-ras mutation patterns of the pancreatic cancers, we were unable to distinguish which case had recurrent or second cancers.…”

Section: Discussionmentioning

confidence: 91%

Two Case Reports of Resectable Cancer in the Remnant Pancreas after Pancreatectomy for Invasive Ductal Carcinoma of the Pancreas

Iwakura

Shirai

Maeda

et al. 2018

International Surgery

View full text Add to dashboard Cite

Abstract:Introduction: Pancreatic cancer has an extremely poor prognosis. There are several reports on resectable cancer in the remnant pancreas after pancreatectomy; however, few have compared K-ras mutation patterns to clarify recurrent or second primary cancers. Case presentations: Here, we report on two cases of cancer in the remnant pancreas after total pancreatectomy for invasive ductal carcinoma. Case 1: A 56-yearold man underwent pancreaticoduodenectomy for cancer of the pancreatic head. However, serum carbohydrate antigen (CA19-9) was again elevated 23 months later. A tumor in the pancreatic tail was detected on abdominal computed tomography (CT) and total pancreatectomy was performed. Histological examination of the tumors from both operations revealed moderately differentiated adenocarcinoma and the surgical margins of both resected specimens were free of cancerous cells. The K-ras gene mutation was detected at codon 12V of exon 1 in both cancers. Case 2: A 72-year-old woman underwent distal pancreatectomy for cancer of the pancreatic body. However, serum CA19-9 was again elevated 4 years postoperatively. A tumor of the pancreatic head was detected on abdominal CT and total pancreatectomy was performed. Powered by Editorial Manager® and ProduXion Manager® from Aries Systems CorporationHistological examination of the first and second tumors revealed poorly and moderately differentiated adenocarcinomas, respectively. The surgical margins of both resected specimens were free of cancerous cells. The K-ras gene mutation was detected at codon 12D of exon 1 in both cancers. Conclusion: These patients with rare pancreatic cancers both had metachronous carcinogenesis in the remnant pancreas. Powered by Editorial Manager® and ProduXion Manager® from Aries Systems CorporationCover Letter

show abstract

Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer

Abstract: K-ras mutation status and subtypes may be associated with survival duration in pancreatic cancer patients.

Cited by 94 publications

References 25 publications

Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

RAS isoforms and mutations in cancer at a glance

Two Case Reports of Resectable Cancer in the Remnant Pancreas after Pancreatectomy for Invasive Ductal Carcinoma of the Pancreas

Contact Info

Product

Resources

About